Duane's retraction syndrome (DRS) is a complex congenital eye movement disorder caused by aberrant innervation of the extraocular muscles by axons of brainstem motor neurons. Studying families with a variant form of the disorder (DURS2-DRS), we have identified causative heterozygous missense mutations in CHN1, a gene on chromosome 2q31 that encodes a2-chimaerin, a Rac guanosine triphosphatase-activating protein (RacGAP) signaling protein previously implicated in the pathfinding of corticospinal axons in mice. We found that these are gain-of-function mutations that increase a2-chimaerin RacGAP activity in vitro. Several of the mutations appeared to enhance a2-chimaerin translocation to the cell membrane or enhance its ability to self-associate. Expression of mutant a2-chimaerin constructs in chick embryos resulted in failure of oculomotor axons to innervate their target extraocular muscles. We conclude that a2-chimaerin has a critical developmental function in ocular motor axon pathfinding.
O cular motility and binocular vision de pend on the precise innervation of six extraocular muscles by the oculomotor, trochlear, and abducens cranial motor neurons (fig. S1A) (1). Disruptions in these developmen tal processes can cause complex congenital eye movement disorders (2, 3) , the most common of which is Duane's retraction syndrome (DRS) with an incidence in the general population of about 0.1%. Individuals with DRS have restricted abduction and in some cases adduction of their eyes, with retraction of the globe upon attempted adduction. Postmortem studies of sporadic DRS reveal absence of the abducens motor neurons and cranial nerve, with anomalous innervation of its target, the lateral rectus muscle, by a branch of the oculomotor nerve (fig. S1B) (4, 5) .
Four pedigrees (IJ, UA, JH, and FY; fig. S1D ) segregating a DRS variant as a dominant trait are reported to map to the DURS2 locus on chro mosome 2q31 (6 8) . Examinations of affected family members established that although some have a phenotype indistinguishable from sporad ic DRS, overall they have a higher incidence of bilateral involvement and of vertical movement abnormalities (Fig. 1A) (8 10) . Consistent with these clinical findings, our magnetic resonance (MR) imaging of members of pedigrees FY and JH revealed that, in addition to absent or hypo plastic abducens nerves and aberrant lateral rec tus innervation by the oculomotor nerve, some individuals had hypoplastic oculomotor nerves and small oculomotor innervated muscles (10) . Thus, mutations in the DURS2 gene appear to affect Rac-GTP levels are reduced by overexpression of wildtype a2-chimaerin relative to empty vector, and are further reduced in cells expressing each mutant, but are elevated with overexpression of a guanine nucleotide exchange factor, myc-ephexin (27). (B) Densitometric analysis of Rac-GTP levels normalized to total Rac and V5-a2-chimaerin levels. Values are expressed as percent of wild-type a2-chimaerin (mean T SEM, n = 6 to 10). The difference between the reduction of Rac-GTP levels for each mutant compared to wild-type a2-chimaerin is significant by one-way analysis of variance (ANOVA) with Dunnett's adjustment (F = 9.89, *P < 0.03, **P < 0.005, ***P < 0.0001). (C) a2-Chimaerin translocation examined by immunoblots of total, soluble, and pellet fraction of wild-type and mutant a2-chimaerin with or without 10 mM PMA stimulation. (D) Graphical representation of translocation after PMA treatment, expressed as percent of a2-chimaerin remaining in the soluble fraction (mean T SEM, n = 3). Enhanced translocation compared to wild-type is significant for L20F, Y143H, A223V, and P252Q by one-way ANOVA with Dunnett's adjustment (F = 21.00, *P < 0.0001). (E) GFP-a2-chimaerin immunoprecipitates with V5-wild type or V5-L20F a2-chimaerin in the presence of PMA, and minimally in its absence. (F) In the presence of PMA, immunoprecipitation of wild-type a2-chimaerin is enhanced by all mutant a2-chimaerins relative to the wild type except G228S and E313K, which were equivalent to wild-type a2-chimaerin. Results were consistent over at least four independent experiments (see also fig. S6 , F and G).
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To identify the DURS2 gene, we further ana lyzed the recombination events that defined the published DURS2 critical region (6, 7), reducing it from 9.9 to 4.6 Mb ( fig. S2, A (Fig. 1B) . All are predicted to alter amino acids that are conserved in eight different species ( fig. S2D ).
The Rho family member Rac is a GTPase that is active when GTP bound; it serves as a regula tor of downstream intracellular signaling cascades controlling cytoskeleton dynamics, including the growth and development of dendrites and axons. Rac is inactivated by 12 Rac GTPase activating proteins (GAPs) in the mammalian genome (11) , including a1 and a2 chimaerin (encoded by CHN1) and paralogs b1 and b2 chimaerin (en coded by CHN2). In the rodent brain, a2 chimaerin has been shown to serve as an effector for axon guidance (12 16) , whereas a1 chimaerin appears to play a later role in dendritic pruning (17, 18) .
CHN1 is alternatively spliced, and the a1 chimaerin promoter lies in intronic sequence up stream of a2 chimaerin exon 7 (19) . Thus, the two isoforms share a RacGAP domain that inter acts with and down regulates Rac activity, as well as a C1 domain that binds to diacylglycerol (DAG), a membrane associated phorbol ester signaling lipid. Only a2 chimaerin contains an N terminal Src homology 2 (SH2) domain (20, 21) . Three DURS2 mutations alter amino acids unique to a2 chimaerin, whereas four alter resi dues shared by a1 and a2 chimaerin (Fig. 1C  and table S1 ). Because we cannot distinguish be tween the two groups clinically, the DURS2 pheno type most likely results from altered a2 chimaerin function.
In situ studies in rats (20, 21) revealed widespread embryonic neuronal expression of a2 chimaerin mRNA. Expression in the caudal brainstem and cephalic flexure peaked at embryonic day (E) 12.5, whereas mouse embryonic expression peaked overall at E10.5 ( fig. S3, A and B) , both con sistent with expression of a2 chimaerin in de veloping ocular motor neurons. We found similar widespread expression of a2 chimaerin mRNA during human development, strongest at Carne gie stage (CS) 15 and CS16 in the midbrain and hindbrain (Fig. 2, fig. S3 , C to E, and fig. S4 ). Therefore, although expressed in developing ocu lar motor neurons, the expression pattern alone does not account for the striking restriction of the DURS2 phenotype.
All seven amino acids altered by DURS2 mu tations are conserved in a2 chimaerin's paralog, , (E), and (G) to (I)] or a-bungarotoxin (F); constructs as labeled. All GFP control (D), 28% of wild type (E), and only 5 to 13% of mutant a2-chimaerin electroporated oculomotor nerves extend normally from the midbrain neuroepithelium, at left, past the dorsal rectus muscle (dr), ciliary ganglion (*), and ventral (vr) and medial (mr) recti to innervate the first target, the ventral oblique (vo) muscle. Nerves expressing mutant a2-chimaerin have a higher incidence of aberrant branching [arrow in (F) with higher-magnification inset] and defasciculation than the wild type ( fig. S7 ). Remarkably, 72% of wild-type a2-chimaerin (G), 87% of L20F a2-chimaerin (H), and 71% of G228S a2-chimaerin (I) electroporated nerves stall in the vicinity of the dr muscle. Scale bars, 200 mm; lr, lateral rectus.
www.sciencemag.org SCIENCE VOL 321 8 AUGUST 2008 841 REPORTS b2 chimaerin ( fig. S5, A and B) . Both molecules are predicted to exist in inactive, closed conforma tions in the cytoplasm, and to unfold and translocate to the membrane in response to DAG signaling, exposing their RacGAP domains and inactivat ing Rac (12, 22) . b2 Chimaerin crystallization revealed that its inactive conformation is main tained by intramolecular interactions that impede access to the Rac and DAG binding sites (22) . Modeling the DURS2 mutations onto the b2 chimaerin structure ( fig. S5 , C to E) (22) To determine whether DURS2 mutations alter the RacGAP activity of a2 chimaerin, we made full length wild type and mutant a2 chimaerin constructs that expressed equally stable proteins in human embryonic kidney (HEK) 293T cells and primary neurons (Fig. 3 and fig. S6A ). Con sistent with a2 chimaerin function, wild type over expression resulted in a reduction in Rac GTP levels from baseline in HEK 293T cells (Fig.  3A) . As predicted, overexpression of each mu tant a2 chimaerin protein resulted in a signifi cant further reduction in Rac GTP levels relative to wild type protein (Fig. 3, A and B) , includ ing when both wild type and L20F a2 chimaerin were coexpressed together in the presence of the DAG analog, phorbol 12 myristate 13 acetate (PMA) ( fig. S6 , B and C). We conclude that all seven DURS2 mutations behave as dom inant gain of function alleles (these and other data for each mutation are summarized in table S1).
Next, we quantified the amount of wild type and mutant a2 chimaerin translocated to the HEK 293T cell membrane before and after stimulation with PMA. About 15% of wild type a2 chimaerin, but significantly greater frac tions of L20F, Y143H, A223V, and P252Q a2 chimaerin mutant proteins, translocated to the membrane fraction in a PMA dose dependent manner (Fig. 3, C and D, and fig. S6 , D and E). Thus, these four mutant residues appear to en hance membrane translocation and RacGAP activity by destabilizing the closed conformation of a2 chimaerin in response to PMA.
Individuals with DURS2 DRS harbor one mutant and one wild type CHN1 allele. There fore, we performed coimmunoprecipitation experi ments to investigate whether mutant hyperactivated a2 chimaerin could interact with the wild type protein, thus potentially recruiting the wild type pool to the membrane and further reducing Rac activity in vivo. a2 Chimaerin and each of the seven mutants were precipitated minimally by wild type a2 chimaerin in the absence of PMA, and to a much greater extent in its presence; these results suggest that a2 chimaerin can complex with itself in a manner partially dependent on the PMA dose (Fig. 3, E and F, and fig. S6F ). In addition, in the presence of PMA, the interaction of wild type a2 chimaerin with all mutants ex cept G228S and E313K was enhanced relative to its interaction with itself (Fig. 3F) . Neither wild type nor L20F a2 chimaerin coimmunoprecipi tated with a1 chimaerin (fig. S6G) ; this result supports a direct or indirect association of a2 chimaerin with itself that may involve its SH2 domain.
On the basis of our findings that DURS2 mutations hyperactivate a2 chimaerin, we hypoth esized that overexpressing a2 chimaerin may result in aberrant axon development in vivo. To test this idea, we used the chick in ovo system to overexpress a2 chimaerin in the embryonic ocu lomotor nucleus. This nucleus is more amenable than the abducens to electroporation, its devel opment in chick has been defined (23), and we previously showed that some DURS2 DRS indi viduals have clinical and MR findings supporting a primary defect in oculomotor nerve development (8 10) . Similar to rodents and humans, chick a2 chimaerin mRNA is expressed in neuroepithelia at stages of cranial motor neuron development (E4), and specifically in the developing oculo motor nucleus at the stage of axon extension and branching (E6) (Fig. 4, A and B) . We electro porated embryonic chick midbrains with green fluorescent protein (GFP) tagged wild type and mutant a2 chimaerin (L20F and G228S) and GFP alone control constructs at E2. These were ana lyzed between E5.5 ( fig. S7 ), when oculomotor axons have extended along an unbranched tra jectory to their distal target, the ventral oblique muscle (vo), and E6, when branching to the other target muscles has ensued (Fig. 4 , C to I) (23) . All 18 GFP control embryos showed a normal projection pattern in which the oculomotor nerve reached the ventral oblique muscle and branched correctly into other target muscles by E6 (Fig.  4D) (23) . In the majority (71 to 87%) of embryos overexpressing wild type or mutant constructs, the oculomotor nerve stalled and its axons ter minated prematurely adjacent to the dorsal rectus muscle (Fig. 4, G to I ). In addition, 67% of embryos overexpressing mutant constructs dis played aberrant branching and/or defasciculation of the oculomotor nerve, whereas only 24% of embryos overexpressing wild type constructs did so ( Fig. 4F and fig. S7 , A to H). Regardless of the construct we used, the electroporated ocu lomotor nucleus appeared normal in size and neuron cell bodies displayed normal sorting, including normal migration across the midline (fig. S7, I and J) (23), consistent with a pri mary defect in axon rather than cell body de velopment. Taken together, these observations suggest that elevated RacGAP activity as a result of hyperactivated mutant or overexpressed wild type a2 chimaerin results in deregulation of nor mal oculomotor axon development.
Eph receptors and ephrins (24) , as well as neuropilin receptors and semaphorins (25) , are expressed in developing cranial motor nuclei in the chick and/or rodent. Several recent papers report that a2 chimaerin interacts with the EphA4 receptor and inactivates Rac in response to ephrin/ EphA4 signaling (13 16) . Loss of a2 chimaerin impairs EphA4 forward signaling in vivo and eliminates ephrin induced growth cone collapse in vitro (13 16) . a2 Chimaerin has also been implicated in semaphorin 3A induced growth cone collapse (12) . EphA4 receptor stimulation can recruit and activate phospholipase C g1, ele vating DAG levels (26) . Therefore, mutant a2 chimaerin may be hyperactivated in response to chemorepellents such as ephrins or semaphorins, resulting in pathological inactivation of Rac and altered transduction of downstream signals (fig .  S8 , A to C).
Mice with loss of a2 chimaerin have dis rupted ephrin/EphA4 signaling and elevated Rac GTP levels, with a phenotype limited to a hopping rabbit like gait resulting from excessive and aber rant midline crossing of corticospinal tract axons and spinal interneuron projections, with no cra nial nerve defects reported (13 15) . We have now identified human a2 chimaerin mutations that enhance its function, reduce Rac GTP levels, and lead to an ocular motor phenotype as a result of errors in cranial motor neuron development. It is remarkable that the up and down regulation of such a widely expressed signaling molecule results in two restricted and apparently non overlapping phenotypes. It remains to be deter mined in which signaling pathways a2 chimaerin functions in corticospinal and cranial motor axons and why these different motor circuits are unique ly vulnerable to different perturbations in Rho GTPase activity. The prevention of autoimmunity requires the elimination of self-reactive T cells during their development and maturation. The expression of diverse self-antigens by stromal cells in the thymus is essential to this process and depends, in part, on the activity of the autoimmune regulator (Aire) gene. Here we report the identification of extrathymic Aire-expressing cells (eTACs) resident within the secondary lymphoid organs. These stromally derived eTACs express a diverse array of distinct self-antigens and are capable of interacting with and deleting naïve autoreactive T cells. Using two-photon microscopy, we observed stable antigen-specific interactions between eTACs and autoreactive T cells. We propose that such a secondary network of self-antigen-expressing stromal cells may help reinforce immune tolerance by preventing the maturation of autoreactive T cells that escape thymic negative selection.
I mmunological tolerance to self is essential in the prevention of autoimmune disease. Mechanisms of central tolerance are medi ated in part through the expression of a wide array of otherwise tissue specific self antigens (TSAs) such as insulin and thyroglobulin in specialized medullary thymic epithelial cells (mTECs) (1 3). The thymic expression of many of these TSAs is dependent on the autoimmune regulator (Aire) gene (4, 5) , and mutations in Aire lead to severe, multiorgan, tissue specific autoimmunity in both mice (4, 6) and humans (7, 8) . Although these results reveal a role for thymic Aire, self tolerance must continue to be enforced after T cells leave the thymus. Con sistent with this fact, Aire expression is also detectable outside the thymus, notably in the secondary lymphoid tissues (4, 9) , although the identity and function of such extrathymic Aire expressing cells remain unclear (10, 11) . Here we identify a population of extrathymic Aire expressing cells and examine a potential role for Aire in maintaining peripheral tolerance.
To accurately label Aire expressing cells in vivo, we employed a bacterial artificial chro mosome (BAC) transgenic approach (12) using the murine Aire locus modified to drive expres sion of green fluorescent protein (Gfp) fused to an autoimmune diabetes related self antigen gene, islet specific glucose 6 phosphatase related pro tein (Igrp) (Fig. 1A) (13) . IGRP is a pancreatic b cell specific protein against which autoreactive CD8 T cells are produced in both mouse and human autoimmune diabetes (14 17) . We elected to include Igrp in our transgenic construct be cause it is not detectable in the thymus (fig. S1A) and because an IGRP specific T cell re ceptor (TCR) transgenic line (8.3) (14) can be used to monitor interactions of Igrp Gfp expressing cells. To verify the fidelity of the BAC transgene in recapitulating endogenous Aire expression in the resultant Adig (Aire driven Igrp Gfp) transgenic mice, thymic sec tions were co stained for Aire and GFP, reveal ing thymic GFP expression highly restricted to Aire expressing cells in the medulla (Fig.  1B and fig. S1B ). By flow cytometry, GFP + cells were detectable specifically within the mTEC compartment (Fig. 1C) , with approx imately 30 to 40% of mTECs being GFP positive. GFP + mTECs expressed uniformly high levels of class II major histocompatibil ity complex (MHC) and CD80 (Fig. 1D) , as in previous studies of Aire expressing mTECs (3, 11, 18) .
To test how the introduction of IGRP into the thymic medullary epithelium might affect T cell selection, we compared 8.3 TCR transgenic and 8.3/Adig double transgenic mice. Tetramer staining confirmed that the 8.3/Adig double transgenic mice showed a significant decrease in the percent and avidity of IGRP specific CD8 + T cells in the thymus (Fig. 1E ) and in the periphery ( fig. S1C ). Further, although IGRP reactive CD8 + T cells were readily detected in the polyclonal wild type NOD background, they were completely absent in Adig NOD mice ( fig. S1D ). To test the functional impact of this negative selection, 8.3 and 8.3/Adig mice were followed for diabetes incidence, and 8.3/Adig mice were completely protected from disease (Fig. 1F) .
In a broad tissue survey using immuno fluorescent anti GFP staining, expression of the transgene was undetectable in most tissues, but distinct populations of extrathymic transgene expressing cells were observed within the lymph nodes and spleen ( fig. S2A ). These extra thymic Aire expressing cells (eTACs) were generally con fined to the T cell zones of the secondary lymph oid organs and preferentially localized to T cell B cell boundary regions (Fig. 2, A and B) . Immu nofluorescent co stains showed these cells to be negative for B cell (B220), fibroblastic re ticular cell (gp38 and ERTR 7), and dendritic cell (CD11c) markers, but positive for class II MHC (Fig. 2, A and B) . Reciprocal bone marrow chimeras demonstrated that many of This PDF file includes:
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Materials and Methods
Subjects and clinical data. The clinical phenotype and linkage to the DURS2 region for pedigrees IJ (S1, S2), UA (S3), JH and FY (S4, S5) were reported previously, while pedigrees RF, IS, and AB are reported here for the first time. Participating members of pedigrees IJ and UA were enrolled by Dr. Timothy Stout and Dr. Nick Gutowski, respectively, with approval of their institutional review boards / research ethics committees. The remaining five pedigrees were enrolled in the ongoing Institutional-Review-Board approved congenital cranial dysinnervation disorder study in the Engle Laboratory at Children's Hospital Boston. Each participating individual provided informed consent, was interviewed and examined by one or more of the authors, and provided a peripheral blood or salivary sample from which genomic DNA was extracted using Puregene (Gentra Systems, Inc.) and purifier solution kit (DNA Genotek Inc.). The diagnosis of Duane's retraction syndrome in each family member was based on ophthalmologic examination using Huber classification (S6). Orbital and MRI data from members of pedigrees JH and FY were previously reported (S5).
Genotyping and reduction of the DURS2 region. Linkage to the DURS2 region was tested in familial Duane's retraction syndrome pedigrees by the analysis of polymorphic markers D2S2330, D2S335, D2S326, D2S2314 and D2S364 as previously described (S4). The DURS2 region was reduced by refining previously reported recombination events in affected members of pedigrees IJ and UA (S1, S3). Polymorphic di-, tri-and tetranucleotide repeats within the region of potential reduction were identified using the UCSC Genome Browser [http://genome.ucsc.edu/cgi-bin/hgGateway] and primers for amplification of the repeat regions were designed and purchased (Invitrogen). Primer sequences are available on request.
Mutation screening. We screened affected members from pedigrees IJ, FY, UA, and JH (the four published pedigrees that mapped independently to the DURS2 region) for mutations in the coding exons of the 22 genes in the refined DURS2 region. The 16 smaller pedigrees were screened for mutations in CHN1 only. The primers sets for CHN1 and the remaining genes that were screened are available on request. Northern Blotting. Alpha2-chimaerin specific regions were amplified by Marathon-ready mouse embryo cDNA (Clontech) and Marathon-ready human fetal brain cDNA (Clontech) with Advantage2 Taq (Clontech). Mouse 2-chimaerin specific probe (400 base pairs (bps) probe corresponding to 61-461 bps in NM_001113246) was amplified using the following primers: 5'-GCTCTGACCCTGTTCGATACAG ATGA-3' and 5'-GCAATGTATTCTGCTGCCTTGGTTTCAA-3'. The human 2-chimaerin specific probe (540 bps corresponding to 471-1010 bps in NM_001822) was amplified using the following primers; 5'-TTACAATGGCCCTGACCCTGTTTG-3' and 5'-CCCCATCCTGGCCTGTAGAATCT-3'. After purification with QIAquick Gel Extraction Kit (Qiagen), the PCR products were labeled by -32 PdCTP by PCR. The control probes ( -actin) were labeled with -32 P-dCTP by Random primed DNA labeling kit (Invitrogen). The blots (Seegene and Clontech) were incubated in prehybridization solution at 68 ºC for 30 minutes followed by incubation in hybridization solution containing 1.7-2.0 cpm/ml of -32 PdCTP labeled probe and 1mg herring sperm DNA (SIGMA) at 68 ºC for two hours. Blots were then washed with Wash Solution I (2xSSC/0.05%SDS) twice for 15 minutes at room temperature followed by Wash Solution II (0.1x SSC/0.1%SDS) twice for 15 minutes at 50 ºC. Blots were exposed at -80ºC for one day to two weeks and the films developed.
Human embryonic and fetal tissue collection. Human embryonic and fetal samples were collected through the Joint MRC-Wellcome Trust Human Developmental Biology Resource (HDBR) at Newcastle University. The samples were collected following British national guidelines (S7) from terminated pregnancy material, with appropriate maternal written consent and approval from the Newcastle and North Tyneside NHS Health Authority Joint Ethics Committee. Tissues were collected into cold 1x phosphate buffered saline (PBS), separated from surrounding tissue, and fixed overnight in 4% paraformaldehyde at 4°C, before short-term storage at 4°C in 70% ethanol. Placental tissue for karyotype analysis was sampled prior to fixation of the tissue. The stage of development was assessed on the basis of external features according to the Carnegie staging protocol (S8) modified for use with individual embryonic samples rather than in comparisons of several embryos simultaneously (S9, S10).
Human embryonic and fetal tissue in situ hybridization. The human 2-chimaerin specific probe (574-1031bps in NM_001822) for in situ hybridization was amplified from Marathon-ready human fetal brain cDNA (Clontech) with Advantage2 Taq (Clontech) using the following primers; 5'-TACCTGTACT TGCGAGGTGGAAAACAGA-3' and 5'-ATGTCAACCTTTTCTCTGACACCCCATC-3'. PCR product was cloned into pCRII-TOPO vector (Invitrogen) and linearized by EcoRV or BamH1, for SP6 (antisense) or T7 (sense) transcription, respectively. The HDBR gene expression service Expression vector preparation. For mammalian expression constructs, full-length 2-chimaerin was amplified from marathon-ready human fetus brain cDNA (Clontech) using KOD Hifi DNA polymerase (TOYOBO/Novagen) with the following primers; 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTC AATGGCCCTGACCCTGTTTGATA-3' and 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCTT AAAATAAAATGTCTTCGTTTTTG-3' (with the underlined sequence the linker region for BP recombination in Gateway system). The PCR product was confirmed by appropriate restriction enzyme digestion and direct sequencing, and was cloned into the entry vector (pDONR TM 221) of Gateway system (Invitrogen). Each of the seven CHN1 missense mutations detected in DURS2 pedigrees was individually introduced into entry clones using Quick change Site-Directed Mutagenesis Kit (Stratagene) and subsequently confirmed by direct sequence. Each insert was then cloned into pcDNA3.1/nV5-DEST TM (N-terminal V5 tag) (Invitrogen) and pcDNA-DEST TM 53 (N-terminal GFP-fusion) (Invitrogen) by LR recombination. The sequence of each construct was again confirmed by direct sequencing. The molecular weights of the generated proteins and equal expression levels were confirmed by Western blotting. For the chick expression constructs, wild-type, L20F and G228S mutant full length cDNA derived from the entry clone were isolated from the each entry clone and were cloned into a bicistronic pCAGGS-IRES-GFP vector in which expression is driven by a chick -actin promoter with a CMV enhancer (S12).
Rac-GTP Activation Assay. V5-empty, V5-wild-type-2-chimaerin, V5-mutant-2-chimaerin constructs were transiently transfected into HEK293T cell using Fugene6 (Roche). Myc-ephexin transfection was used as a control, as it is predicted to elevate RacGTP levels (S13). After 48 hours incubation in full media, the Rac1 Activation Assay Kit (Upstate) was used to isolate Rac-GTP by binding to the p21 binding domain of PAK1. Cells were lysed with 500 l of ice cold 1xMLB buffer, and the lysate was then pre-cleared with gluthathione speharose (Amersham Biosciences) and reacted with 10 l of a 50% slurry of p21 binding domain (PBD)-beads for 1 hour at 4 ºC. The beads were then washed, boiled in loading buffer and spun down. The supernatant was run in a 12% Bris-Tris gel (Invitrogen) and transferred to nitrocellulose membrane (Invitrogen) for Western blot analysis using a mouse monoclonal anti-Rac1 antibody (BD Transduction Laboratories). Immunoblot images were quantified using Scion Image [http://www.scioncorp.com/], background was subtracted, and each quantity was normalized to total Rac and then to total V5-2-chimaerin. Next, to mimic the effect of heterozygous DURS2-DRS mutations on RacGAP activity, we compared the RacGTP levels following transfection of 6 g of V5-WT, a mixture of 3 g of V5-WT and 3 g of V5-L20F, or 6 g of V5-L20F-2-chimaerin into HEK293T cells without and with the addition of PMA. For statistical analysis, V5-wild-type-2-chimaerin was arbitrarily set to 100% and each mutant value expressed as a percent of V5-wild-type 2-chimaerin. One-way analysis of variance (one-way ANOVA) with Dunnett's adjustment was conducted using GraphPad Prism 5 for Mac OS X Software v. 5.0a (www.graphpad.com) and SAS statistical software (v.8.1, SAS Institute, Cary, NC).
Quantification of 2-chimaerin translocation. Subcellular fractions were prepared from HEK293T cells 48 hours after transfection with V5-2-chimaerin-wild-type or each of the seven V5-2-chimaerinmutants using Fugene6 (Roche). Cells were pretreated for 30 min with 5 M of bisindolylmaleimide I (LC Labs) to inhibit PKC, and then stimulated with 0-10 M of PMA for 20 min as reported by Canagarajah et al. (S14) . Cells were sonicated in hypotonic buffer (S15) and were centrifuged at 100,000 g at 4ºC for 1 hour to separate the soluble and pellet fractions. The pellet fraction, containing both membrane and cytoskeleton, was then resuspended with equal volume of CSK buffer (S15). Immunoblotting was performed with mouse monoclonal anti-V5 antibody (Invitrogen) and HRPconjugated Donkey anti-mouse IgG (Jackson Immuno Research Lab). The signal intensities for wild-type and each of the seven mutants were quantified using Scion Image and plotted in a graphical format with the Y-axis representing: [soluble fraction /total fraction following 10 M PMA treatment] as a percent of [soluble fraction / total fraction without PMA treatment]. The significance of the statistical differences in the behavior of the mutants to wild-type was calculated by one-way ANOVA with Dunnett's adjustment as described above.
Co-immunoprecipitation experiments. 3 g V5-2-chimaerin vectors and 3 g GFP-fused 2-chimaerin vectors were transiently co-transfected into HEK293T cells. After 48 hours incubation, the cells were pretreated with 5 M of PKC inhibitor for 30 minutes and then a subset were stimulated with 10 M of PMA for 30 minutes. Cells were solubilized in lysis buffer [50mM Tris-HCl (pH7.6), 150mM NaCl, 1mM EDTA (pH8.0), 0.5% NP-40, 10% glycerol, 0.5mM DDT, 10mM NaF, 1mM Na 3 VO 4 protein inhibitor cocktail-EDTA free (Roche)] on ice for 30 minutes, and the lysate was centrifugated at 14000 rpm at 4°C for 20min. The supernatant was pre-cleared by incubation with rec-Protein G-Sepharose 4B Conjugate (ZYMED Laboratories, Invitrogen) at 4°C for 1 hour and then incubated with rabbit polyclonal anti-GFP antibody (ab6556) (Abcam) and rec-Protein G-Sepharose 4B Conjugate at 4°C for 16 hours. The rec-Protein G-Sepharose was then washed with cold 1x PBS for 15 minutes x 4, mixed with loading buffer, and boiled. Samples were run in a 12% Bris-Tris gel (Invitrogen) and transferred to nitrocellulose membrane (Invitrogen). Signal was detected by mouse monoclonal anti-V5 antibody (Invitrogen) and HRP-conjugated Donkey anti-mouse IgG (Jackson Immuno Research Lab). As controls, first V5-wildtype-or L20F-2-chimaerin vectors at concentrations of 0.6 g and 1.0 g were transiently cotransfected with 1.0 g GFP-2-chimaerin into HEK293T cells and co-immunoprecipitation performed as above. Given positive co-IP at these transfection levels in the presence of 10 M of PMA, 5 g V5-1-chimaerin vectors and 1 g GFP-fused wild-type or L20F-2-chimaerin vectors were transiently cotransfected into HEK293T cells and co-immunoprecipitation and western blotting was performed as above.
Overexpression of wild-type and mutant 2-chimaerin in primary hippocampal neurons. Rat primary hippocampal neurons were isolated from E18.5 rat embryonic brain and 1 x10 6 neurons were plated on 6-well plates coated with 0.5 mg/ml poly D-lysine (Chemicon) and cultured in neurobasal medium (Invitrogen) supplemented with B27 supplement (Invitrogen), 0.5mM L-glutamine, 25 M glutamate, 100 U/ml penicillin, and 100 mg/ml streptomycin. After 48 hours incubation, the neurons were co-transfected with 3.5 g V5-2-chimaerin and 0.5 g pEGFP-N3 vectors using lipofectamine 2000 (Invitrogen). 48 and 72 hours following transfection, neurons were rinsed once with cold 1x PBS and then lysed on ice for 30 minutes in RIPA lysis buffer [50mM Tris-HCl (pH7.6), 150mM NaCl, 1mM EDTA (pH8.0), 1% NP-40, 0.1% SDS, 0.1% sodium deoxycholate, 0.5mM DDT, 10mM NaF, 1mM Na3VO4, protein inhibitor cocktail-EDTA free (Roche)]. The lysate was then centrifuged at 14000 rpm at 4°C for 10 min and the supernatant mixed with loading buffer and boiled. Western blotting was performed as described above. As a control for 2-chimaerin protein molecular weight, one lane was loaded with wildtypeV5-2-chimaerin overexpressed in HEK293T cells.
Chick in situ hybridization. Chick 2-chimaerin clone (NM_001012952) was a kind gift of Dr. Randy Caldwell (S16). The chick -chimaerin riboprobe (nucleotides 386-819) was amplified using the following primers: 5'-AGGCAGCAGAATACATTGCC-3' and 5'-TAGTGTGGTAAGGTCACAGC-3' and cloned into pCRII-TOPO (Invitrogen). For in situ hybridization on cryostat sections, slides were washed briefly in 1x PBS and processed as described by Myat et al. (S17) .
Electroporation of chick embryos in ovo.
Hens' eggs were incubated to Hamburger-Hamilton (HH) stage 10-11 (E2) and processed for electroporation as described by Momose et al. (S18). The midbrain vesicle or hindbrain, as appropriate, was microinjected with the DNA construct. Following electroporation, eggs were sealed and reincubated for 3 -4 days to HH stage 27-30 (E5-6). Embryos were partially bisected and immunohistochemistry was performed on whole-mounts as described previously (S19), using chicken anti-GFP antibody (Abcam, UK) and mouse monoclonal anti-sarcomeric myosin antibody mf20 (Developmental Studies Hybridoma Bank) or using rabbit polyclonal anti-GFP antibodies (Molecular Probes) and 4 μM Alexa647-conjugated -bungarotoxin (Molecular Probes). Flattened preparations were viewed from the medial side to visualise the oculomotor nerve. Flatmounted brainstems were stained with anti-Islet1/2 (clone 39.4D5, Developmental Studies Hybridoma Bank, University of Iowa) and anti-GFP (rabbit polyclonal, Molecular Probes) antibodies, and were viewed from the ventral side to visualize the oculomotor nucleus. Both preparations were imagined using a laser-scanning confocal microscope (Nikon EC1 or Zeiss LSM510 Meta). 
(A-C) Schematic representation of extraocular muscle (EOM) innervation in (A) normal individuals, (B) sporadic Duane's retraction syndrome (DRS), and (C) DURS2-DRS.
In the normal state (A), four recti and two oblique EOM move the globe and the levator palpebrae superioris (LPS) muscle raises the eyelid. The oculomotor nucleus (depicted in blue) is composed of five motor subnuclei that send their axons in the oculomotor nerve; the axons in the superior branch of the oculomotor nerve innervate the LPS and superior rectus (SR) muscles, and the axons in the inferior branch innervate the medial rectus (MR), inferior rectus (IR), and inferior oblique (IO) muscles. The trochlear nucleus (depicted in brown) sends its axons in the trochlear nerve to innervate the superior oblique (SO) muscle. The abducens nucleus (depicted in green) is composed of motor neurons and interneurons. The motor neurons send their axons to innervate the lateral rectus (LR) muscle, which has been cut into two pieces in the schematic in order to visualize the oculomotor nerve. In Duane's retraction syndrome (B), human postmortem studies (S20, S21) have reported that the abducens motor neurons are depleted (depicted as a dotted abducens nucleus), and the abducens cranial nerve is absent or markedly depleted (hatched thin green line). The lateral rectus muscle can be inappropriately innervated by aberrant branches off the oculomotor nerve (thin blue branches off oculomotor to LR muscle). This misinnervation of the lateral rectus by axons destined for the medial and inferior recti is proposed to result in co-contraction and globe retraction, a hallmark of DRS. (C) In our clinical and MRI studies of DURS2-DRS, we found evidence of the changes reported in sporadic DRS (B). In addition, however, we found that a subset of DURS2-DRS patients have a hypoplastic oculomotor nerve and can have small oculomotor-innervated muscles. This is depicted as thin blue oculomotor nucleus in (C).
(D) Schematic pedigree drawings of the four DURS2 families previously reported to map to the DURS2 locus. Squares = males, circles = females, hatches = deceased, filled black squares/circles = affection with Duane's retraction syndrome, and "+" sign = participation in the study.
(E) Schematic pedigree drawings of the three previously unpublished DURS2 pedigrees harboring CHN1 mutations. The DRS phenotype in RF is linked to the DURS2 locus, while in IS and AB it is consistent with linkage. Affection status co-segregates with the DURS2-DRS affected haplotype and CHN1 mutation in all participants within each pedigree and, as predicted by haplotype analysis, clinically unaffected individuals FY VI:4 (S4), RF III:7, and AB III:2 harbor disease mutations, supporting 95% penetrance of CHN1 mutations underlying DRS. published DURS2 critical region (9 9Mb) refined DURS2 region (4 6Mb) )   cen   172  174  176  178  180  182  175  177  179  181  183  173   Apukuttan et al 1999  Evans et al 2000   GTPBP9  CIR  SCRN3  GPR155  WIPF1  ATF2  CHRNA1  ATP5G3  HOXD13  HOXD12  HOXD11  HOXD10  HOXD9  HOXD8  HOXD4  HOXD3  HOXD1  MTX2  HNRPA3  AGPS  PDE11A  DRB1  NFE2L2  OSBPL6  PRKRA  DFNB59  FKBP7  PLEKHA3 In (B) , the top depicts a schematic cytogenetic representation of chromosome 2, indicating the published 2q31-q32 DURS2 critical region, while the bottom is a schematic physical map from ~171 to ~184 Mb along chromosome 2. In both (A) and (B), arrows indicate the relative position of CHN1. Evans et al published the DURS2 centromeric recombination event that occurred in UA III:7 (A) within a 2.7 Mb region between recombinant marker D2S326 (small green font on left in B) and first internal nonrecombinant marker analyzed, D2S2188 (small red font in B) (S3). Appukuttan et al published the DURS2 telomeric recombination events in IJ III:3 (A) which fell within the 5 Mb region between recombinant marker D2S364 (small green font on right in B) and first analyzed nonrecombinant marker D2S138 (small red font in B) (S1). By designing primers to short tandem repeats found on of the UCSC Genome Browser Human, we reduced the critical region by maximally reducing the distance between the internal nonrecombinant and first recombinant marker (A and B) . This reduced the centromeric recombination in UA III:7 to between recombinant DSCA3 (chr2; 174556614-174556903 bps) and DSCA4 (chr2; 174637754-174638136 bps) and the telomeric recombination in IJ III:3 to between D2SATT3 (chr2; 178561724-178561878 bps) and D2TA4 (chr2; 179218986-179219179 bps). The new refined 4.6 Mb DURS2 region is denoted by brackets between the new recombinant markers, DSCA3 and D2TA4, indicated in (B) by large bold green font with (+) above them. The refined first internal nonrecombinant markers, DSCA4 and D2SATT3, are indicated in (B) by large bold red font with (-) above them. Thirty known genes fell within the newly refined DURS2 region. Among these, 22 were sequenced and mutations were identified only in CHN1. CHN1 is located between polymorphic short tandem repeat markers D2S2188 and D2S2314 as denoted by a blue arrow. The eight genes not sequenced were GTPBP9, WIPF1, OSBPL6, PRKRA, DFNB59, FKBP7, PLEKHA3, TTN.
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(C) Automated genomic sequence analysis of one affected individual from each DURS2-DRS pedigree showing the seven heterozygous mutations in CHN1. The nucleotide substitution and predicted corresponding normal and mutated amino acid residue are indicated under each triplet codon. For pedigree FY, note that the second nucleotide of exon 2 is mutated, and the corresponding amino acid is encoded by the last nucleotide in exon 1 (T) and the first two nucleotides in exon 2. Thus, wild-type TTA encodes a leucine while mutant TTT encodes a phenylalanine.
(D) Human 2-chimaerin protein sequence aligned with homologs surrounding each mutation (boxed in black). The predicted human 2-chimaerin protein shares 99.8%, 98.5%, 94.4%, 94.2%, 93.1%, 88.8% and 39.1% identity with the chimpanzee, rhesus monkey, mouse, rat, chick, frog, and fruit fly, respectively. The CHN1 mutations associated with DURS2-DRS alter residues that are highly conserved among these homologs. (A-E) For each blot, the upper hybridization is with an 2-chimaerin specific CHN1 probe that recognizes a band of 2.6 kb, and the lower hybridization is with a control -actin probe. (A) In mouse whole embryos, expression begins at ~E10.5 and is maximal between E10.5-E12.5. (B) In mouse adult brain, high expression is observed in brain and heart with lower expression in testis and kidney. (C) In human fetal tissue, mRNA is abundant in brain, with lower levels in lung and kidney. (D) In human adult tissue, a transcript is expressed primarily in brain and heart, with low expression observed in small intestine, placenta and lung. (E) In human adult brain tissue, 2-chimaerin mRNA is expressed abundantly in the cerebral cortex and at a lower level in putamen, cerebellum, medulla, and spinal cord. The closest section hybridized with the sense probe is (D), in which the 'staining' of the tissue is background and is a different color to that seen with the antisense hybridizations. Interestingly, as in chick (Fig 4) and unlike reported expression in the rat (S22), expression is in both the ventricular layer and in post-mitotic neurons (Fig. 2, fig. S3C (A) Human 2-chimaerin (NP_001813) and 2-chimaerin (1XA6) protein sequence alignment with amino acid numbering indicated above and below the protein sequence, respectively. The SH2, C1 and RacGAP domains are underlined in blue, orange and pink, respectively. Alignment reveals 72.5% identity overall, with 78.2% identify in the SH2 domain, 51.7% in the linker between the SH2 and C1 domains, 93.8% in the C1 domain, and 75.5% in the RacGAP domain (ClustalW alignment). The seven CHN1 mutations associated with DURS2-DRS are boxed in red and all are conserved between these two paralogs.
(B) Table indicating the equivalent 2-chimaerin residues for each of the 2-chimaerin mutations.
(C) Three-dimensional schematic of the predicted closed 2-chimaerin crystal structure with the SH2, C1 and RhoGAP domain regions highlighted in blue, yellow, and pink, respectively. The predicted positions of the 2-chimaerin residues altered by DURS2-DRS mutations are highlighted by dark blue amino acid side chains and generally cluster in and around the C1 domain. 50 for phorbol ester-induced translocation (S14). G235 is the DAG binding site, while residues R311, F315, and E317 interact with Rac. (E) 2-chimaerin. The positions of the seven 2-chimaerin amino acid residues altered by DURS2-DRS mutations are indicated in red. Of these, G228S and Y143H are indicated as red circles as they are predicted to be involved in intramolecular interactions as indicated, and G228S is predicted to be the DAG biding site. L20F and I126M are indicated as red squares as they correspond to the green squares in (D) and would be predicted to alter translocation to the membrane when mutated. E313K, P252Q, and A223V are indicated by red triangles because no direct predictions could be made as to their behavior. Note, however, that E313K is adjacent to the predicted Rac binding region, while A223V is one amino acid removed from a residue involved in an intramolecular interaction.
Fig S6. Supporting 2-chimaerin hyperactivation and interaction data. (A)
The levels of over-expressed wild-type, L20F-, and G228S-2-chimaerin in hippocampal neurons at 48 and 72 hours after transfection are approximately equal when corrected for transfection efficiency based on the level of GFP (n=2). V5-wildtype-2-chimaerin over-expressed in HEK293T cells provides a size marker. The upper band present in all hippocampal lanes is nonspecific. (B) Rac-GTP levels were measured in HEK293T cells transfected with plasmids encoding V5-2-chimaerin wild-type, a equal mixture of V5-wild-type-and V5-L20F-2-chimaerin ('mixed'), or V5-L20F-2-chimaerin without (left blot) or with (right blot) PMA. Rac-GTP levels are reduced by co-overexpression of mixed and L20F-2-chimaerin compared to wildtype alone. (C) Densitometric analysis of Rac-GTP levels in the presence of PMA normalized to total Rac and V5-2-chimaerin levels. Values are expressed as percent of wild-type 2-chimaerin (mean+SEM, n=3). The difference between the reduction of Rac-GTP levels for either mixed-or L20F-alone is significant when compared to wild-type 2-chimaerin by one-way ANOVA with Dunnett's adjustment (**p<0.005, ***p<0.0001). There is no significant difference between mixed-and L20F-2-chimaerin. (D) A greater percentage of mutant-2-chimaerin than wild-type translocates to the particulate fraction in HEK293T cells in response to PMA, and the degree of translocation is PMA dose dependent. (E) Graph of the densitometric analysis of 2-chimaerin immunoreactivity in the soluble fraction following 0, 1 M, and 10 M PMA. The results are expressed as a percentage of 2-chimaerin in the soluble fraction following PMA compared to the pre-treated cells (mean± SEM, n=6-11). At 10 M PMA, the difference between the percent of wild-type versus L20F that has translocated is statistically significant (P<0.01) using one-way ANOVA followed by Dunnett's post-test. (F) A representative immunoblot demonstrating that wild-type-2-chimaerin complexes with itself in the presence of PMA in a dose-dependent manner. (G) 2-chimaerin immunoprecipitates with wild-type or L20F-2-chimaerin in the presence of PMA when transiently over-expressed in HEK293T cells. In contrast, 1-chimaerin does not immunoprecipitate with wild-type or L20F-2-chimaerin under the same experimental conditions (n=4). Fig 4D) . Neither wild-type nor mutant overexpression altered the initial projection of the OMN (B, D, and E). Defasciculation and ectopic branching was most striking in G228S-expressing embryos, where the nerve showed a frayed appearance with stalling and branches diverging / defasciculating from the main nerve trunk over some distance (D, D', F and Fig. 4F ). This was also seen, however, in L20F-expressing embryos (E, E', G, H) and to a lesser frequency and extent in wild-type (B, C). The somewhat less severe wild-type overexpression phenotype is consistent with the finding that DURS2-DRS mutations enhance 2-chimaerin activity. (I and J) Flatmounted brainstems following electroporation of the right OMN nucleus with wildtype 2-chimaerin at E2 and stained with anti-Islet1 and anti-GFP antibodies at E5.5 (I, HH stage 28) and E6.0 (J, HH stage 30). Compared with the contralateral unelectroporated nucleus, organization of the oculomotor nucleus cell bodies, including the migration across the midline of the ventromedial pool (asterisk in J), appears unaffected by electroporation with wildtype 2-chimaerin (n=11 wild-type and n=7 G228S embryos examined). Predicted to be adjacent to Rac binding site a) MR images published (S5) b) 2-chimaerin L28A increases 2-chimaerin translocation to the membrane following PMA stimulation (S14). c) 2-chimaerin I134A increases 2-chimaerin translocation to the membrane following PMA stimulation (S14). d) 2-chimaerin Y143 is phosphorylated by EphA4 stimulation (S24). e) 2-chimaerin G235 binds phorbol ester (S14)..
